Who are PF-06882961 (Cohorts 1 and 2)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Combination 1, Allr3, D-Col Personal Hygiene Convenience Kit, PF-07104091 monotherapy dose expansion (ovarian), Entecavir+Fuzheng Huayu+TCM Granule, ECx1.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pf-06882961-cohorts-1-and-2.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

PF-06882961 (Cohorts 1 and 2) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PF-06882961 (Cohorts 1 and 2) (pf-06882961-cohorts-1-and-2) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: pharmacological class. Area: Oncology.

marketed pharmacological class molecular target Oncology Live · refreshed every 30 min

Target snapshot

PF-06882961 (Cohorts 1 and 2) (pf-06882961-cohorts-1-and-2) — Pfizer. PF-06882961 is a small molecule with a molecular target.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
PF-06882961 (Cohorts 1 and 2) TARGET	pf-06882961-cohorts-1-and-2	Pfizer	marketed	pharmacological class	molecular target
Combination 1	combination-1	Pfizer	marketed	Combination therapy	Multiple molecular targets
Allr3	allr3	Pfizer	marketed	The pharmacological class of ALLR3 is not specified.	The molecular target of ALLR3 is not specified.
D-Col Personal Hygiene Convenience Kit	col	Pfizer	marketed	not well-documented	various molecular targets
PF-07104091 monotherapy dose expansion (ovarian)	pf-07104091-monotherapy-dose-expansion-ovarian	Pfizer	marketed	small molecule	[insert molecular target]
Entecavir+Fuzheng Huayu+TCM Granule	Entecavir+Fuzheng Huayu+TCM Granule	ShuGuang Hospital	marketed	Nucleoside reverse transcriptase inhibitor + Traditional Chinese Medicine herbal combination	HBV reverse transcriptase (entecavir component); multiple herbal constituents with unclear specific molecular targets
ECx1	ECx1	Oregon Health and Science University	marketed	small molecule	ECx1's molecular target is unknown

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (pharmacological class class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PF-06882961 (Cohorts 1 and 2) — Competitive Intelligence Brief. https://druglandscape.com/ci/pf-06882961-cohorts-1-and-2. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab